What did the court say about FDA orders against Cadila? ALSO WATCHAdvertisementAdvocate Birendra Saraf, who represented Cadila, said the FDA stock seizure and stop-sale orders had resulted in significant financial losses to the company, and appealed the court to revoke these directives. However, the court stressed that its primary concern was the impact of the FDA’s order on patients, not fiscal losses for Cadila. Meanwhile, the FDA defended actions taken against Cadila, alleging some of the pharma company’s products carried a similar branding despite containing different active pharmaceutical ingredients (APIs). AdvertisementThe FDA claims that using similar branding carries a serious risk of medication errors as consumers and doctors may confuse one medicine with another.